The Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) study examined the effects of the SGLT-2 inhibitor dapagliflozin according to frailty status. Here, SLC5A2 is linked to heart failure.